![](https://ml.globenewswire.com/media/a14fd627-7ccb-45e2-95fe-792bbfb83231/small/2020-0227-cognition-logo-for-gnw-png.png)
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes ...
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - …